Construct and promote the continuous transformation and optimization of the industrial ecology, and strive to create a "nuclear explosion point" for scientific and technological innovation
From August 4 to 10, 2024, the Zhangjiang Science Hall in Pudong, Shanghai welcomed tens of thousands of biomedical practitioners, and the "three conferences and one exhibition" that attracted much attention from the industry were held here. Our company is honored to be invited to attend this event and focus on the cutting-edge trends in the field of biomedicine together with many industry elites. This conference was hosted by Yimao Medical, with Zhangjiang Group as a supporting unit and jointly presented, covering multiple stages of R&D, clinical, CMC, and production.
At the scene, Wu Qiang, member of the Standing Committee of Shanghai Pudong New Area and deputy district mayor, Yuan Tao, party secretary and chairman of Shanghai Zhangjiang (Group) Co., Ltd., deputy general manager of Shanghai Zhangjiang (Group) Co., Ltd. and president of Shanghai Pudong Life Sciences Industry Development Co., Ltd. Manager Lou Qi and other guests cut the ribbon for the opening of the 2024BPD Seventh Biopharmaceutical Process Development Conference. The 2024BPD Seventh Biopharmaceutical Process Development Conference invited a total of 150 speakers, 30 forums, and presented 105 professional reports. It was an industry benchmark meeting focusing on the entire process of biopharmaceuticals from process development to commercial production. The content was in-depth on biopharmaceuticals. In the field of technology, we focus on innovation and development. Colleagues in the industry have in-depth interactions and collision of opinions to promote the development and cooperation of biomedicine.
The 2024IDC Third New Drug Research and Development Impact Conference will explore research and development trends and lay out cutting-edge pipelines through keynote speeches, round-table discussions, closed-door meetings, etc.; break through technical bottlenecks and promote innovative research and development. The forum content covers popular targets, technology platforms, and cutting-edge technologies Tools, complete case sharing, covering small molecule drugs, antibody drugs, cell therapy, gene therapy, nucleic acid drugs and other subdivisions, promote R&D technology exchanges, share valuable experience, and avoid R&D detours.
The 2024GCD Innovative Drug Global Clinical Development Strategy Conference focuses on drug clinical development innovation, takes global development as the starting point, and focuses on indication selection strategies, innovative track plan design, and introduction of global clinical resources. Based on cases, we explore how to improve clinical effectiveness through program design and optimization; we are commercial-oriented and think about how to select appropriate indications based on the current clinical development status in different regions around the world; we aim at innovative products and explore new clinical trials for new drug development. .
This "three conferences and one exhibition" lasts for seven days. As an industry conference focusing on the entire process of biopharmaceuticals from process development to commercial production, the 2024BPD 7th Biopharmaceutical Process Development Conference will focus deeply on the field of biopharmaceutical process and share industry knowledge. The 2024IDC Third New Drug Research and Development Impact Conference covers small molecule drugs, antibody drugs, cell therapy, gene therapy, nucleic acid drugs and other subdivisions, from popular targets, technology platforms, cutting-edge technology tools to complete case sharing, to promote research and development Technical exchanges and sharing of valuable experiences. The 2024GCD Innovative Drug Global Clinical Development Strategy Conference takes global development as the starting point, focusing on indication selection strategies, innovative track plan design, and introduction of global clinical resources. Our company and Shanghai Zhangjiang and many other units and enterprises have a common vision in participating in this event, which is to firmly aim at the cutting-edge trends of global science and technology, actively cultivate layout and expand in depth in the future track, and attract global innovation Entrepreneurial talents gather together in cell and gene therapy, AI+ medicine, synthetic biology, modern traditional Chinese medicine, medical robots, and health care. In the old and cutting-edge diagnostics and other subdivided fields, we will build and promote the continuous transformation and optimization of the industrial ecology by establishing open innovation centers, establishing transformation platforms, establishing industrial alliances, creating space carriers, and building characteristic parks, and strive to create a "nuclear explosion" of scientific and technological innovation. "Point" will help the biopharmaceutical industry shine brighter on the global stage and contribute more to human health.
We believe that with the joint efforts of all parties, the biopharmaceutical industry will usher in more vigorous development. Our company will also take an active role in this process and work with colleagues in the industry to create a better future.